Clinical Trial Update: Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK [Phase 2]

View source ↗

Summary

A Phase 2 trial (INVINCIBLE-4-SAKK) testing intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy for early triple-negative breast cancer is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• INT230-6

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING